Literature DB >> 8979252

Flumazenil does not affect the increase in rat hippocampal extracellular glutamate concentration produced during thioacetamide-induced hepatic encephalopathy.

P McArdle1, D H Penning, F Dexter, J D Reynolds.   

Abstract

Hepatic encephalopathy (HE) is a neuropsychiatric disorder that often occurs as a consequence of acute or chronic liver failure. Previous reports have suggested that alterations in amino acid neurotransmission, particularly glutamate, may play an important role in the pathogenesis of HE. The objectives of the present study were to test the hypothesis that extracellular glutamate concentration is increased during HE, and to determine if flumazenil, a benzodiazepine antagonist, alters the extracellular concentration of glutamate during HE. The experimental approach involved using microdialysis probes to measure rat hippocampal extracellular glutamate concentration. HE was brought about as a result of thioacetamide-induced liver failure. Thioacetamide produced behavioral and metabolic effects, such as somnolence, hyperventilation and hyperammonemia, consistent with stage three HE. Comparison with saline-treated rats demonstrated that HE was associated with a significant increase (p = 0.010) in extracellular hippocampal glutamate concentration. Administration of flumazenil caused a transient increase in arousal level, but did not affect the increase in glutamate concentration (p = 0.93). These results corroborate the theory that glutamate neurotransmission is altered during HE and suggest that the flumazenil arousal of HE rats is not mediated by a change in extracellular glutamate concentration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8979252     DOI: 10.1007/bf02029494

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  32 in total

1.  Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure.

Authors:  A S Basile; R D Hughes; P M Harrison; Y Murata; L Pannell; E A Jones; R Williams; P Skolnick
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

Review 2.  Neuropharmacologic modulation of hepatic encephalopathy: experimental and clinical data.

Authors:  P Ferenci; A Herneth; A Püspök; P Steindl
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

Review 3.  Astrocyte-neuron interactions in hyperammonemia and hepatic encephalopathy.

Authors:  J Albrecht; L Faff
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

Review 4.  Flumazenil in the treatment of hepatic encephalopathy.

Authors:  C D Howard; C F Seifert
Journal:  Ann Pharmacother       Date:  1993-01       Impact factor: 3.154

5.  Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: characterization of an improved model and study of amino acid-ergic neurotransmission.

Authors:  C Zimmermann; P Ferenci; C Pifl; C Yurdaydin; J Ebner; H Lassmann; E Roth; H Hörtnagl
Journal:  Hepatology       Date:  1989-04       Impact factor: 17.425

6.  The anticonvulsant effect of the benzodiazepine antagonist, Ro 15-1788: an EEG study in 4 cases.

Authors:  G Scollo-Lavizzari
Journal:  Eur Neurol       Date:  1984       Impact factor: 1.710

7.  Monitoring of neurotransmitter amino acids by means of an indwelling cisterna magna catheter: a comparison of two rodent models of fulminant liver failure.

Authors:  M S Swain; M Bergeron; R Audet; A T Blei; R F Butterworth
Journal:  Hepatology       Date:  1992-10       Impact factor: 17.425

8.  Cerebral metabolic and histological effects of thioacetamide-induced liver failure.

Authors:  J Peeling; L Shoemaker; T Gauthier; A Benarroch; G R Sutherland; G Y Minuk
Journal:  Am J Physiol       Date:  1993-09

9.  Thioacetamide-induced hepatic necrosis. II. Pharmacokinetics of thioacetamide and thioacetamide-S-oxide in the rat.

Authors:  W R Porter; M J Gudzinowicz; R A Neal
Journal:  J Pharmacol Exp Ther       Date:  1979-03       Impact factor: 4.030

10.  Synaptosomal glutamate transport in thioacetamide-induced hepatic encephalopathy in the rat.

Authors:  K N Oppong; K Bartlett; C O Record; H al Mardini
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

View more
  6 in total

1.  Genistein Alleviates Neuroinflammation and Restores Cognitive Function in Rat Model of Hepatic Encephalopathy: Underlying Mechanisms.

Authors:  Ajaz Ahmad Ganai; Mohammad Husain
Journal:  Mol Neurobiol       Date:  2017-02-21       Impact factor: 5.590

2.  Extracellular concentrations of taurine, glutamate, and aspartate in the cerebral cortex of rats at the asymptomatic stage of thioacetamide-induced hepatic failure: modulation by ketamine anesthesia.

Authors:  J Albrecht; W Hilgier; M Zielińska; S Januszewski; M Hesselink; G Quack
Journal:  Neurochem Res       Date:  2000-11       Impact factor: 3.996

Review 3.  Effects of hyperammonemia and liver failure on glutamatergic neurotransmission.

Authors:  Pilar Monfort; María-Dolores Muñoz; Amina ElAyadi; Elena Kosenko; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

4.  Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil.

Authors:  H P Meyer; D A Legemate; W van den Brom; J Rothuizen
Journal:  Metab Brain Dis       Date:  1998-09       Impact factor: 3.584

5.  Effect of glutamine synthesis inhibition with methionine sulfoximine on the nitric oxide-cyclic GMP pathway in the rat striatum treated acutely with ammonia: a microdialysis study.

Authors:  Wojciech Hilgier; Michal Wegrzynowicz; Michal Maczewski; Andrzej Beresewicz; Simo S Oja; Pirjo Saransaari; Jan Albrecht
Journal:  Neurochem Res       Date:  2007-08-29       Impact factor: 3.996

Review 6.  Contributions of microdialysis to new alternative therapeutics for hepatic encephalopathy.

Authors:  Liliana Rivera-Espinosa; Esaú Floriano-Sánchez; José Pedraza-Chaverrí; Elvia Coballase-Urrutia; Aristides Iii Sampieri; Daniel Ortega-Cuellar; Noemí Cárdenas-Rodríguez; Liliana Carmona-Aparicio
Journal:  Int J Mol Sci       Date:  2013-08-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.